was successfully added to your cart.

Cart

Company News

INT Awarded with Phase I SBIR Grant Funding from the NIH

By June 5, 2014 No Comments

Innovative NeuroTechnologies, Inc. (INT) in collaboration with James W. Larrick, M.D., Ph.D. of Panorama Research, Inc. (PRI) have been awarded $293,000 Phase I grant from the National Institute of Health (NIH) Small Business Innovation Research (SBIR) program to conduct preliminary “proof-of-concept” animal efficacy studies for the N-terminal Tau monoclonal antibody (i.e., INT-1 mAb) in relevant transgenic mouse models for tauopathies.  The group has proposed to develop a novel therapeutic approach for neurodegenerative tauopathies like Alzheimer’s disease (AD) with the use a recombinant adenoassociated viral (AAV) vector to achieve long-term, stable delivery of the N-terminal (INT-1) mAb pass the blood-brain barrier (BBB) and into the affected neurons of the central nervous system (CNS).

Leave a Reply